EU Clinical Trial Information System (CTIS)

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

I searched for some studies on AstraZeneca Clinical Trials, and found these studies that may also be of interest to you.
Here is the link to my search results

Official Title

In Turkey statin compliance is lower than EU countries. (EURIKA). We will assess the underlying causes of statin incompliance.  The investigators will build patient and physician education programs to improve compliance in TURKEY. Our aim is to assess patients' and physicians' attitudes to statins by mean of HABIT Patient and Physician survey respectively.

Observational study to understand patients' and physicians' attitudes to Statins in TurkeY

Research Site

Research name

- Total score
 - Effectiveness of cholesterol-lowering medications
 - Association of high doses with adverse experiences
 - Risk of high cholesterol
 - Severity of high cholesterol
 - Frustration with the process of care
 - Difficulty in following advice / making changes
 - Doctor-patient communication
 - Communication about cholesterol

- Total score
 - Effectiveness of statins
 - Patients view titration negatively
 - Risk associated with higher doses
 - Close enough to goal
 - Urgency of getting to goal
 - Utility of diet and exercise
 - Time and resources to counsel patients
 - Physician self-efficacy in treating patients to goal

- Age
 - Sex
 - Smoking habits
 - Educational level
 - Professional status
 - Place of residence
 - Income level
 - Healthcare insurance level

- Date of diagnosis
- Current disease status: Physical examination results (vital signs and anthropometric measurements)
- Cardiovascular risk factors
- Relevant co-morbidities
- Cholesterol levels (LDL-C) at inclusion (if available)
- Number of hospitalizations during the last 12 months
- Duration of statin use in the past year

- List of poor compliance (discontinuation) causes in the past one year 
- Treatment discontinuation (statins), reported causes 
- Time to discontinuation of statin therapy (in early stage/medium term/long term) 
- Change in lipid levels and other laboratory findings (i.e. hepatic and muscle enzymes) during statin use (before, during and after discontinuation of statin therapy) 
- List of alternative drug and non-drug therapies received after discontinuation of statin and number (%) of patients who switched to those alternative therapies 
- Concomitant treatments

Observational study to understand patients' and physicians' attitudes to Statins in TurkeY - STAY

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

NIS-CTR-XXX-2012/1 Study Report Synopsis

Trial Results Summaries

Contacts

Contact

Contact Backup

Investigators

Principal Investigator